

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	7717582
<b>Application Number:</b>	09993647
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	1010
<b>Title of Invention:</b>	omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
<b>First Named Inventor/Applicant Name:</b>	Bernd Riedl
<b>Customer Number:</b>	23599
<b>Filer:</b>	Csaba Henter/Caitlin Sickler
<b>Filer Authorized By:</b>	Csaba Henter
<b>Attorney Docket Number:</b>	BAYER 18A
<b>Receipt Date:</b>	01-JUN-2010
<b>Filing Date:</b>	27-NOV-2001
<b>Time Stamp:</b>	12:53:03
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	P1- AdjeiAPhaseIStudyofBAY43900 6andGefitinibinPatientswithaR efractory.pdf	69532  a7968799ac7dd7b573f8f5ef74bd8037e219 ef4a	no	1

### Warnings:

### Information:

2	NPL Documents	P2- AhmadKinaseInhibitionwithBA Y439006inRenalCellCarcinoma. pdf	590309  de2ea12045e15fc558c233d5c35aaf18d8250810	no	5
<b>Warnings:</b>					
<b>Information:</b>					
3	NPL Documents	P3- AMORNPHINOLTHAMETALPER SISTENTACTIVATIONOFTHEAKT PATHWAYINHEADANDNECK. pdf	631504  2c7295ce354c13ef84411605ea65fcbabdb22060	no	9
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	P4a-Arora-et-al-Clin-Cancer- Res-v11-n6-p2272.pdf	3025798  eaa7e2b0f5ae3e62b138419e61956c9c35afe562	no	13
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	P4b-Ascierto-et-al-Anticancer- Res-v24-n6-p4255.pdf	706202  8c6c0c89cfdaf4fe7b1f396187a2e25843304e505	no	4
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	P4-ARNONEETAL- SELECTIVITIESINTHEOXIDATION OFTERTIARYAMINES.pdf	832589  aa246b0753cf437cb71e3262b2264dedc203bb3d	no	12
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	P5- AuclairBAY43-9006Sorafenibisa PotentInhibitorofFLT3Tyrosine KinaseSignaling.pdf	59931  57ec9e3fecaf69331d098cf04f3bf297a40d2c6c	no	1
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	P6-Audiaetal.pdf	1262890  070ff0171847d65b26de6b05447c3213150d108b	no	9
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	P7-Avuruch.pdf	815295  51bf24d8c0b69a2e06dd49805760c27eeea27fa4	no	5
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	P8-AWADAETAL.pdf	725020  6210c6c32d60c0017efe4d0d2c77e029c037e569	no	7
<b>Warnings:</b>					
<b>Information:</b>					

11	NPL Documents	P9-BADGERETAL.pdf	1974500	no	9
			e925c77842c2dd5c85c3c74a3f8f58aef169024		
Warnings:					
Information:					
12	NPL Documents	P9a-BakaetalAreviewoflatestclinical.pdf	881500	no	10
			202bd76ecc9ef89ff22ad8af30596eae06ee8cd4		
Warnings:					
Information:					
13	NPL Documents	P10-BALANTLPETAL-METABOLICCONSIDERATIONS.PDF	2630313	no	35
			b0b0ccb1be945d2031ffa466e3328f7e6666be74		
Warnings:					
Information:					
14	NPL Documents	P11-Bandoetal-AssnIntratumoral.pdf	981813	no	10
			57d8c22bbfe98ca35f8dce78ee2f8b29e92c39c9		
Warnings:					
Information:					
15	NPL Documents	P12-BanerjeeetalMurineCoronaviruss.pdf	1351877	no	12
			7e0d3a867e0479d47892815fa75bb323ce553058		
Warnings:					
Information:					
16	NPL Documents	P13-BankstonAScaleableSynthesisofBAY43-9006APotentRafKinaseInhibitorfortheTreatmentofCancer.pdf	365909	no	5
			be97be697a5dfac647f08c2694be8113da78d958		
Warnings:					
Information:					
17	NPL Documents	P14-BARNETTETALIDENTIFICATIONANDCHARACTERIZATIONOFPLECSTRIN.pdf	325377	no	10
			bb622cbde6dffe98bc9378ad860e0cc84123fe90		
Warnings:					
Information:					
18	NPL Documents	P14a-BaumannRafinducesNF-kb.pdf	757635	no	6
			aa30de3336481ce7820a8b10c78e6f8832a9d5df		
Warnings:					
Information:					
19	NPL Documents	P15-BAYER-NCT0010413.pdf	176926	no	3
			bd12b7f32a16a5d4e0db8ea20a83355278a76c82		
Warnings:					
Information:					

20	NPL Documents	P16-BELLACOSAETAL- MOLECULARALTERATIONSOF HEAKT2.pdf	944427  30d590bf135dcb6af2e0dd10d290f6eff1b8 17ef	no	6
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>				19109347	
<p><b>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</b></p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>  <b>If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</b></p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>  <b>If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</b></p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b>  <b>If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</b></p>					